Centene Corporation Reports 2018 First Quarter Results And Adjusts 2018 Guidance
In summary, the 2018 first quarter results were as follows:
Total revenues (in millions) |
$ |
13,194 |
|
Health benefits ratio |
84.3 |
% |
|
SG&A expense ratio |
10.5 |
% |
|
GAAP diluted EPS |
$ |
1.91 |
|
Adjusted Diluted EPS (1) |
$ |
2.17 |
|
Total cash flow provided by operations (in millions) |
$ |
1,846 |
|
(1) A full reconciliation of Adjusted Diluted EPS is shown on page six of this release. |
First Quarter Highlights
March 31, 2018 managed care membership of 12.8 million, an increase of 684,000 members, or 6% overMarch 31, 2017 .- Total revenues for the first quarter of 2018 of
$13.2 billion , representing 13% growth, compared to the first quarter of 2017. - Health benefits ratio (HBR) of 84.3% for the first quarter of 2018, compared to 87.6% in the first quarter of 2017.
- Selling, general and administrative (SG&A) expense ratio of 10.5% for the first quarter of 2018, compared to 9.8% for the first quarter of 2017.
- Adjusted SG&A expense ratio of 10.3% for the first quarter of 2018, compared to 9.3% for the first quarter of 2017.
- Operating cash flow of
$1.8 billion for the first quarter of 2018, representing 5.5x net earnings. - Diluted EPS for the first quarter of 2018 of
$1.91 , compared to$0.79 for the first quarter of 2017. - Adjusted Diluted EPS for the first quarter of 2018 of
$2.17 , compared to$1.12 for the first quarter of 2017. Adjusted Diluted EPS for the first quarter of 2018 was higher than our previous expectations by approximately$0.12 per diluted share due to the delay in the financing for the acquisition ofNew York State Catholic Health Plan, Inc. d/b/a Fidelis Care New York (Fidelis Care ) (Proposed Fidelis Acquisition).
Other Events
- In
April 2018 , we received regulatory approvals from theNew York Department of Health and theNew York Department of Financial Services for the Proposed Fidelis Acquisition . The Proposed Fidelis Acquisition remains subject to regulatory approval from theNew York Attorney General and certain closing conditions. - In
April 2018 , we completed the acquisition ofMHM Services, Inc. (MHM), a national provider of healthcare and staffing services to correctional systems and other government agencies. Under the terms of the agreement,Centene also acquired the remaining 49% ownership of Centurion, the correctional healthcare services joint venture betweenCentene and MHM. - In
March 2018 , we acquired an additional 61% ownership inInterpreta Holdings, Inc. (Interpreta), a clinical and genomics data analytics business, bringing our total ownership to 80%. - In
March 2018 , we completed the acquisition ofCommunity Medical Holdings Corp. , d/b/aCommunity Medical Group (CMG), an at-risk primary care provider serving approximately 70,000 Medicaid, Medicare Advantage, andHealth Insurance Marketplace patients inMiami-Dade County, Florida . - In
March 2018 , we made a 25% equity method investment in RxAdvance, a full-service pharmacy benefit manager (PBM), and expect to use its platform to improve health outcomes and reduce avoidable drug-impacted medical and administrative costs. This partnership includes both a customer relationship and a strategic investment in RxAdvance. As part of the initial transaction,Centene has certain rights to expand its equity investment in the future. - In
March 2018 , ourArizona subsidiary, Health Net Access, was selected to provide physical and behavioral healthcare services through the Arizona Health Care Cost Containment System Complete Care program in the Central region and the Southern region. Pending regulatory approval and successful completion of readiness review, the three-year agreement, with the possibility of two two-year extensions, is expected to commence onOctober 1, 2018 .
Membership
The following table sets forth our membership by line of business:
|
|||||
2018 |
2017 |
||||
Medicaid: |
|||||
TANF, CHIP & |
5,776,600 |
5,714,100 |
|||
ABD & LTSS |
866,000 |
825,600 |
|||
|
454,500 |
466,900 |
|||
Total Medicaid |
7,097,100 |
7,006,600 |
|||
Commercial |
2,161,200 |
1,864,700 |
|||
Medicare & MMP (1) |
343,400 |
328,100 |
|||
Correctional |
157,300 |
141,900 |
|||
Total at-risk membership |
9,759,000 |
9,341,300 |
|||
TRICARE eligibles |
2,851,500 |
2,804,100 |
|||
Non-risk membership |
218,900 |
— |
|||
Total |
12,829,400 |
12,145,400 |
|||
(1) Membership includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and Medicare-Medicaid Plans (MMP). |
The following table sets forth additional membership statistics, which are included in the membership information above:
|
|||||
2018 |
2017 |
||||
Dual-eligible (2) |
438,200 |
458,700 |
|||
|
1,603,800 |
1,188,700 |
|||
Medicaid Expansion |
1,057,400 |
1,091,300 |
|||
(2) Membership includes dual-eligible ABD & LTSS and dual-eligible Medicare membership in the table above. |
Statement of Operations: Three Months Ended
- For the first quarter of 2018, total revenues increased 13% to
$13.2 billion , from$11.7 billion in the comparable period in 2017. The increase over prior year was due to growth in theHealth Insurance Marketplace business in 2018, expansions and new programs in many of our states in 2017 and 2018, and the reinstatement of the health insurer fee in 2018. These increases were partially offset by lower revenues inCalifornia , which is a result of the removal of the in-home support services (IHSS) program from its Medicaid contract. - Sequentially, total revenues increased 3% over the fourth quarter of 2017 mainly due to growth in the
Health Insurance Marketplace business and the reinstatement of the health insurer fee. These increases were partially offset by approximately$700 million of revenue received in the fourth quarter of 2017 associated with pass through payments from theState of California , which were recorded in premium tax revenue and premium tax expense. - HBR of 84.3% for the first quarter of 2018 represents a decrease from 87.6% in the comparable period in 2017. The year-over-year decrease was primarily a result of membership growth in the
Health Insurance Marketplace business, lower medical costs in our Medicaid business, and the reinstatement of the health insurer fee in 2018. These decreases were partially offset by new or expanded health plans, which initially operate at a higher HBR, and increased flu-related costs. - HBR decreased sequentially from 87.3% in the fourth quarter of 2017. The decrease was primarily attributable to performance and seasonality in the
Health Insurance Marketplace business and the reinstatement of the health insurer fee in 2018. These HBR improvements were partially offset by the increase in flu-related costs over the fourth quarter of 2017. - The SG&A expense ratio was 10.5% for the first quarter of 2018, compared to 9.8% for the first quarter of 2017. The year-over-year increase was primarily a result of growth in the
Health Insurance Marketplace business, as well as increased acquisition related expenses over the first quarter of 2017. These increases were partially offset by the impact of Penn Treaty assessment expense recognized in the first quarter of 2017. - Sequentially, the SG&A expense ratio decreased from 10.9% in the fourth quarter of 2017, primarily due to increased selling costs associated with open enrollment in the fourth quarter of 2017 and the
$40 million contribution to our charitable foundation in the fourth quarter of 2017. These decreases were partially offset by increased acquisition related expenses over the fourth quarter of 2017 and increased variable compensation expenses related to earnings performance in the first quarter of 2018. - The Adjusted SG&A expense ratio was 10.3% for the first quarter of 2018, compared to 9.3% for the first quarter of 2017. The year-over-year increase is primarily a result of growth in the
Health Insurance Marketplace business, which operates at a higher SG&A expense ratio. - Sequentially, the Adjusted SG&A expense ratio decreased from 10.5% in the fourth quarter of 2017, primarily due to increased selling costs associated with open enrollment in the fourth quarter of 2017, partially offset by increased variable compensation expenses related to earnings performance in the first quarter of 2018.
Balance Sheet and Cash Flow
At
Cash flow provided by operations for the three months ended
Outlook
The Company's annual guidance for 2018 has been updated for the following items:
- An increase to GAAP diluted EPS and Adjusted Diluted EPS of
$0.05 associated with the performance of the business in the first quarter of 2018; - A change in the timing of the anticipated closing of the Proposed Fidelis Acquisition from
April 1, 2018 toJuly 1, 2018 , as well as a change in the assumed timing of the equity and debt financing fromMarch 1, 2018 toMay 1, 2018 . The ultimate timing of the financings will depend on market conditions; - The impact of undertakings that
Centene is expected to enter into as part of the regulatory approval process for the Proposed Fidelis Acquisition with theNew York State Department of Health . It is expected that one of the undertakings, among others, will include a$340 million contribution byCentene to theState of New York to be paid over a five-year period for initiatives consistent with our mission of providing high quality healthcare to vulnerable populations withinNew York State . Upon the closing of the Proposed Fidelis Acquisition, the present value of the$340 million contribution to theState of New York , estimated to be approximately$325 million , will be expensed in SG&A; and - The net effect of the acquisitions of CMG, MHM, and Interpreta and the investment in RxAdvance.
A rollforward of certain captions of the Company's current 2018 guidance from its previous guidance is as follows (Total Revenues in billions, per share data in dollars):
Total Revenues |
GAAP diluted EPS |
Adjusted Diluted EPS |
|||||
|
|
|
|
||||
Q1 Performance |
— |
0.05 |
0.05 |
||||
Timing of Fidelis Care Financing & Acquisition |
(2.7) - (2.9) |
(0.21) |
(0.25) |
||||
Undertakings for the Proposed Fidelis Acquisition |
— |
(1.26) |
— |
||||
Recent Acquisitions and Investments |
0.3 - 0.5 |
(0.13) |
— |
||||
|
|
|
|
||||
The Company's full updated annual guidance for 2018 is as follows:
Full Year 2018 |
|||||||||
Low |
High |
||||||||
Total revenues (in billions) |
$ |
58.2 |
$ |
59.0 |
|||||
GAAP diluted EPS |
$ |
4.36 |
$ |
4.70 |
|||||
Adjusted Diluted EPS (1) |
$ |
6.75 |
$ |
7.15 |
|||||
HBR |
85.9 |
% |
86.4 |
% |
|||||
SG&A expense ratio |
10.2 |
% |
10.7 |
% |
|||||
Adjusted SG&A expense ratio (2) |
9.4 |
% |
9.9 |
% |
|||||
Effective tax rate |
34.0 |
% |
36.0 |
% |
|||||
Diluted shares outstanding (in millions) |
196.5 |
197.5 |
|||||||
(1) |
Adjusted Diluted EPS excludes amortization of acquired intangible assets of |
(2) |
Adjusted SG&A expense ratio excludes acquisition related expenses of |
Conference Call
As previously announced, the Company will host a conference call
Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the
A webcast replay will be available for on-demand listening shortly after the completion of the call for the next twelve months or until
Non-GAAP Financial Presentation
The Company is providing certain non-GAAP financial measures in this release as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally to allow management to focus on period-to-period changes in the Company's core business operations. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
Specifically, the Company believes the presentation of non-GAAP financial information that excludes amortization of acquired intangible assets, acquisition related expenses, as well as other items, allows investors to develop a more meaningful understanding of the Company's performance over time. The tables below provide reconciliations of non-GAAP items ($ in millions, except per share data):
Three Months Ended |
|||||||
2018 |
2017 |
||||||
GAAP net earnings |
$ |
340 |
$ |
139 |
|||
Amortization of acquired intangible assets |
39 |
40 |
|||||
Acquisition related expenses |
21 |
5 |
|||||
Penn Treaty assessment expense (1) |
— |
47 |
|||||
Income tax effects of adjustments (2) |
(14) |
(34) |
|||||
Adjusted net earnings |
$ |
386 |
$ |
197 |
(1) |
Additional expense for the Company's estimated share of guaranty association assessment resulting from the liquidation of the Penn Treaty for the three months ended |
(2) |
The income tax effects of adjustments are based on the effective income tax rates applicable to adjusted (non-GAAP) results. |
Three Months Ended |
Annual Guidance December 31, |
||||||||
2018 |
2017 |
||||||||
GAAP diluted EPS |
$ |
1.91 |
$ |
0.79 |
|
||||
Amortization of acquired intangible assets (1) |
0.17 |
0.14 |
|
||||||
Acquisition related expenses (2) |
0.09 |
0.02 |
|
||||||
Penn Treaty assessment expense (3) |
— |
0.17 |
— |
||||||
Adjusted Diluted EPS |
$ |
2.17 |
$ |
1.12 |
|
(1) |
The amortization of acquired intangible assets per diluted share presented above is net of an income tax benefit of |
(2) |
The acquisition related expenses per diluted share presented above are net of an income tax benefit of |
(3) |
The Penn Treaty assessment expense per diluted share presented above is net of an income tax benefit of |
Three Months Ended |
Three Months |
||||||||||
2018 |
2017 |
2017 |
|||||||||
GAAP SG&A expenses |
$ |
1,316 |
$ |
1,091 |
$ |
1,260 |
|||||
Acquisition related expenses |
21 |
5 |
7 |
||||||||
Penn Treaty assessment expense |
— |
47 |
— |
||||||||
Charitable contribution |
— |
— |
40 |
||||||||
Adjusted SG&A expenses |
$ |
1,295 |
$ |
1,039 |
$ |
1,213 |
About
Forward-Looking Statements
The company and its representatives may from time to time make written and oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act ("PSLRA") of 1995, including statements in this and other press releases, in presentations, filings with the
[Tables Follow]
CENTENE CORPORATION AND SUBSIDIARIES |
|||||||
CONSOLIDATED BALANCE SHEETS |
|||||||
(In millions, except shares in thousands and per share data in dollars) |
|||||||
|
|
||||||
(Unaudited) |
|||||||
ASSETS |
|||||||
Current assets: |
|||||||
Cash and cash equivalents |
$ |
5,668 |
$ |
4,072 |
|||
Premium and trade receivables |
3,648 |
3,413 |
|||||
Short-term investments |
507 |
531 |
|||||
Other current assets |
1,153 |
687 |
|||||
Total current assets |
10,976 |
8,703 |
|||||
Long-term investments |
5,535 |
5,312 |
|||||
Restricted deposits |
140 |
135 |
|||||
Property, software and equipment, net |
1,250 |
1,104 |
|||||
|
5,295 |
4,749 |
|||||
Intangible assets, net |
1,519 |
1,398 |
|||||
Other long-term assets |
455 |
454 |
|||||
Total assets |
$ |
25,170 |
$ |
21,855 |
|||
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY |
|||||||
Current liabilities: |
|||||||
Medical claims liability |
$ |
4,771 |
$ |
4,286 |
|||
Accounts payable and accrued expenses |
4,962 |
4,165 |
|||||
Return of premium payable |
515 |
549 |
|||||
Unearned revenue |
638 |
328 |
|||||
Current portion of long-term debt |
4 |
4 |
|||||
Total current liabilities |
10,890 |
9,332 |
|||||
Long-term debt |
5,172 |
4,695 |
|||||
Other long-term liabilities |
1,520 |
952 |
|||||
Total liabilities |
17,582 |
14,979 |
|||||
Commitments and contingencies |
|||||||
Redeemable noncontrolling interests |
8 |
12 |
|||||
Stockholders' equity: |
|||||||
Preferred stock, |
— |
— |
|||||
Common stock, |
— |
— |
|||||
Additional paid-in capital |
4,592 |
4,349 |
|||||
Accumulated other comprehensive (loss) |
(54) |
(3) |
|||||
Retained earnings |
3,104 |
2,748 |
|||||
|
(139) |
(244) |
|||||
Total Centene stockholders' equity |
7,503 |
6,850 |
|||||
Noncontrolling interest |
77 |
14 |
|||||
Total stockholders' equity |
7,580 |
6,864 |
|||||
Total liabilities, redeemable noncontrolling interests and stockholders' equity |
$ |
25,170 |
$ |
21,855 |
CENTENE CORPORATION AND SUBSIDIARIES |
|||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||
(In millions, except per share data in dollars) |
|||||||
(Unaudited) |
|||||||
Three Months Ended |
|||||||
2018 |
2017 |
||||||
Revenues: |
|||||||
Premium |
$ |
11,903 |
$ |
10,638 |
|||
Service |
653 |
527 |
|||||
Premium and service revenues |
12,556 |
11,165 |
|||||
Premium tax and health insurer fee |
638 |
559 |
|||||
Total revenues |
13,194 |
11,724 |
|||||
Expenses: |
|||||||
Medical costs |
10,039 |
9,322 |
|||||
Cost of services |
543 |
441 |
|||||
Selling, general and administrative expenses |
1,316 |
1,091 |
|||||
Amortization of acquired intangible assets |
39 |
40 |
|||||
Premium tax expense |
546 |
590 |
|||||
Health insurer fee expense |
171 |
— |
|||||
Total operating expenses |
12,654 |
11,484 |
|||||
Earnings from operations |
540 |
240 |
|||||
Other income (expense): |
|||||||
Investment and other income |
41 |
41 |
|||||
Interest expense |
(68) |
(62) |
|||||
Earnings from operations, before income tax expense |
513 |
219 |
|||||
Income tax expense |
175 |
87 |
|||||
Net earnings |
338 |
132 |
|||||
Loss attributable to noncontrolling interests |
2 |
7 |
|||||
Net earnings attributable to |
$ |
340 |
$ |
139 |
|||
Net earnings per common share attributable to |
|||||||
Basic earnings per common share |
$ |
1.95 |
$ |
0.81 |
|||
Diluted earnings per common share |
$ |
1.91 |
$ |
0.79 |
|||
CENTENE CORPORATION AND SUBSIDIARIES |
|||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
(In millions) |
|||||||
(Unaudited) |
|||||||
Three Months Ended |
|||||||
2018 |
2017 |
||||||
Cash flows from operating activities: |
|||||||
Net earnings |
$ |
338 |
$ |
132 |
|||
Adjustments to reconcile net earnings to net cash provided by operating activities |
|||||||
Depreciation and amortization |
104 |
86 |
|||||
Stock compensation expense |
33 |
32 |
|||||
Deferred income taxes |
30 |
(51) |
|||||
Changes in assets and liabilities |
|||||||
Premium and trade receivables |
(176) |
59 |
|||||
Other assets |
51 |
89 |
|||||
Medical claims liabilities |
485 |
358 |
|||||
Unearned revenue |
317 |
320 |
|||||
Accounts payable and accrued expenses |
157 |
(237) |
|||||
Other long-term liabilities |
477 |
459 |
|||||
Other operating activities, net |
30 |
1 |
|||||
Net cash provided by operating activities |
1,846 |
1,248 |
|||||
Cash flows from investing activities: |
|||||||
Capital expenditures |
(218) |
(83) |
|||||
Purchases of investments |
(765) |
(582) |
|||||
Sales and maturities of investments |
445 |
343 |
|||||
Acquisitions, net of cash acquired |
(226) |
— |
|||||
Other investing activities, net |
— |
(1) |
|||||
Net cash used in investing activities |
(764) |
(323) |
|||||
Cash flows from financing activities: |
|||||||
Proceeds from long-term debt |
2,015 |
560 |
|||||
Payments of long-term debt |
(1,491) |
(560) |
|||||
Common stock repurchases |
(9) |
(13) |
|||||
Other financing activities, net |
(2) |
3 |
|||||
Net cash provided by (used in) financing activities |
513 |
(10) |
|||||
Net increase in cash, cash equivalents and restricted cash |
1,595 |
915 |
|||||
Cash, cash equivalents, and restricted cash and cash equivalents, beginning of period |
4,089 |
3,936 |
|||||
Cash, cash equivalents, and restricted cash and cash equivalents, end of period |
$ |
5,684 |
$ |
4,851 |
|||
Supplemental disclosures of cash flow information: |
|||||||
Interest paid |
$ |
73 |
$ |
72 |
|||
Income taxes paid |
$ |
1 |
$ |
2 |
|||
Equity issued in connection with acquisitions |
$ |
324 |
$ |
— |
|
|||||||||||||||
SUPPLEMENTAL FINANCIAL DATA FROM CONTINUING OPERATIONS |
|||||||||||||||
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
|||||||||||
2018 |
2017 |
2017 |
2017 |
2017 |
|||||||||||
MANAGED CARE MEMBERSHIP BY STATE |
|||||||||||||||
|
639,800 |
640,500 |
659,500 |
669,500 |
684,300 |
||||||||||
|
92,300 |
85,700 |
89,900 |
91,900 |
98,100 |
||||||||||
|
2,903,600 |
2,877,800 |
2,928,600 |
2,925,800 |
2,980,100 |
||||||||||
|
1,090,600 |
848,800 |
852,600 |
871,100 |
872,000 |
||||||||||
|
581,500 |
483,600 |
476,400 |
540,400 |
568,300 |
||||||||||
|
238,400 |
239,500 |
251,000 |
254,600 |
253,800 |
||||||||||
|
317,400 |
304,500 |
322,900 |
340,000 |
335,800 |
||||||||||
|
151,500 |
129,100 |
127,300 |
130,000 |
133,100 |
||||||||||
|
485,900 |
485,500 |
483,300 |
484,600 |
484,100 |
||||||||||
|
8,900 |
43,000 |
48,300 |
54,100 |
44,200 |
||||||||||
|
2,800 |
2,500 |
2,400 |
2,300 |
2,100 |
||||||||||
|
9,400 |
9,400 |
9,500 |
9,500 |
9,500 |
||||||||||
|
347,600 |
329,900 |
335,600 |
343,600 |
349,500 |
||||||||||
|
329,900 |
269,400 |
272,100 |
278,300 |
106,100 |
||||||||||
|
81,500 |
79,700 |
79,200 |
78,800 |
79,200 |
||||||||||
|
74,600 |
34,900 |
16,800 |
— |
— |
||||||||||
|
82,900 |
74,800 |
76,400 |
77,100 |
77,800 |
||||||||||
|
7,200 |
7,100 |
7,100 |
7,100 |
7,100 |
||||||||||
|
352,800 |
332,700 |
336,500 |
332,700 |
328,900 |
||||||||||
|
199,300 |
205,200 |
209,700 |
213,600 |
211,900 |
||||||||||
|
22,400 |
— |
— |
— |
— |
||||||||||
|
119,300 |
117,800 |
118,600 |
121,000 |
121,900 |
||||||||||
|
22,000 |
22,200 |
22,100 |
22,200 |
21,900 |
||||||||||
|
1,260,100 |
1,233,500 |
1,236,700 |
1,226,800 |
1,243,900 |
||||||||||
|
1,600 |
1,600 |
1,600 |
1,600 |
1,600 |
||||||||||
|
260,800 |
237,800 |
239,600 |
248,500 |
254,400 |
||||||||||
|
74,900 |
70,200 |
70,200 |
70,800 |
71,700 |
||||||||||
Total at-risk membership |
9,759,000 |
9,166,700 |
9,273,900 |
9,395,900 |
9,341,300 |
||||||||||
TRICARE eligibles |
2,851,500 |
2,824,100 |
2,823,200 |
2,823,200 |
2,804,100 |
||||||||||
Non-risk membership |
218,900 |
216,300 |
213,900 |
— |
— |
||||||||||
Total |
12,829,400 |
12,207,100 |
12,311,000 |
12,219,100 |
12,145,400 |
||||||||||
Medicaid: |
|||||||||||||||
TANF, CHIP & |
5,776,600 |
5,807,300 |
5,809,400 |
5,854,400 |
5,714,100 |
||||||||||
ABD & LTSS |
866,000 |
846,200 |
850,300 |
843,500 |
825,600 |
||||||||||
|
454,500 |
463,700 |
467,400 |
466,500 |
466,900 |
||||||||||
Total Medicaid |
7,097,100 |
7,117,200 |
7,127,100 |
7,164,400 |
7,006,600 |
||||||||||
Commercial |
2,161,200 |
1,558,300 |
1,657,800 |
1,743,600 |
1,864,700 |
||||||||||
Medicare & MMP (1) |
343,400 |
333,700 |
331,000 |
327,500 |
328,100 |
||||||||||
Correctional |
157,300 |
157,500 |
158,000 |
160,400 |
141,900 |
||||||||||
Total at-risk membership |
9,759,000 |
9,166,700 |
9,273,900 |
9,395,900 |
9,341,300 |
||||||||||
TRICARE eligibles |
2,851,500 |
2,824,100 |
2,823,200 |
2,823,200 |
2,804,100 |
||||||||||
Non-risk membership |
218,900 |
216,300 |
213,900 |
— |
— |
||||||||||
Total |
12,829,400 |
12,207,100 |
12,311,000 |
12,219,100 |
12,145,400 |
||||||||||
(1) Membership includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and MMP. |
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
|||||||||||||||
2018 |
2017 |
2017 |
2017 |
2017 |
|||||||||||||||
NUMBER OF EMPLOYEES |
34,800 |
33,700 |
32,400 |
31,500 |
30,900 |
||||||||||||||
DAYS IN CLAIMS PAYABLE (a) |
43 |
41 |
42 |
40 |
41 |
||||||||||||||
(a) Days in claims payable is a calculation of medical claims liabilities at the end of the period divided by average claims expense per calendar day for such period. |
|||||||||||||||||||
CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions) |
|||||||||||||||||||
Regulated |
$ |
11,398 |
$ |
9,740 |
$ |
9,633 |
$ |
9,673 |
$ |
10,034 |
|||||||||
Unregulated |
452 |
310 |
308 |
291 |
306 |
||||||||||||||
Total |
$ |
11,850 |
$ |
10,050 |
$ |
9,941 |
$ |
9,964 |
$ |
10,340 |
|||||||||
DEBT TO CAPITALIZATION |
40.6 |
% |
40.6 |
% |
41.5 |
% |
42.5 |
% |
43.3 |
% |
|||||||||
DEBT TO CAPITALIZATION EXCLUDING NON-RECOURSE DEBT (b) |
40.3 |
% |
40.3 |
% |
41.2 |
% |
42.1 |
% |
43.0 |
% |
|||||||||
(b) The non-recourse debt represents the Company's mortgage note payable ( |
|||||||||||||||||||
Debt to capitalization is calculated as follows: total debt divided by (total debt + total equity). |
OPERATING RATIOS
Three Months Ended |
||||||||||
2018 |
2017 |
|||||||||
HBR |
84.3 |
% |
87.6 |
% |
||||||
SG&A expense ratio |
10.5 |
% |
9.8 |
% |
||||||
Adjusted SG&A expense ratio |
10.3 |
% |
9.3 |
% |
||||||
MEDICAL CLAIMS LIABILITY
The changes in medical claims liability are summarized as follows (in millions):
Balance, |
$ |
4,290 |
||||
Reinsurance recoverable |
8 |
|||||
Balance, |
4,282 |
|||||
Incurred related to: |
||||||
Current period |
38,956 |
|||||
Prior period |
(388) |
|||||
Total incurred |
38,568 |
|||||
Paid related to: |
||||||
Current period |
34,446 |
|||||
Prior period |
3,646 |
|||||
Total paid |
38,092 |
|||||
Balance, |
4,758 |
|||||
Plus: Reinsurance recoverable |
13 |
|||||
Balance, |
$ |
4,771 |
||||
The amount of the "Incurred related to: Prior period" above represents favorable development and includes the effects of reserving under moderately adverse conditions, new markets where we use a conservative approach in setting reserves during the initial periods of operations, receipts from other third party payors related to coordination of benefits and lower medical utilization and cost trends for dates of service
View original content:http://www.prnewswire.com/news-releases/centene-corporation-reports-2018-first-quarter-results-and-adjusts-2018-guidance-300635033.html
SOURCE
Car Insurance Injury Claims Lowest This Decade
Former BP CEO Lord Browne Joins Windward’s Board to Extend Startup’s Lead in Maritime Risk Analytics
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News